Ruth Luthi-Carter, PhD, started her independent research group in 2003 at the Swiss Federal Institute of Technology (EPFL) in Switzerland and in 2012 became a full professor at the University of Leicester. Her research group has undertaken groundbreaking work to discover new potential therapeutic targets for brain diseases. She recently joined AC Immune SA as Research Fellow, bringing her molecular neurobiology expertise to the company's translational research.

Dr. Luthi-Carter earned her doctorate in pharmacology and molecular sciences from Johns Hopkins University, where she worked with Professor Joseph Coyle to uncover FOLH1 as the gene encoding an enzyme that subsequently became a therapeutic target for brain diseases and injury. She subsequently undertook postdoctoral research with Professor Anne Young at Harvard’s MassGeneral Institute for Neurodegenerative Disease.